INVO Bioscience (INVO) reported Q3 EPS of ($0.21), $0.09 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $200 thousand.
INVO Bioscience (INVO) reported Q3 EPS of ($0.21), $0.09 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $200 thousand.